BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 24287065)

  • 21. Brentuximab vedotin: an anti-CD30 antibody-drug conjugate.
    Bradley AM; Devine M; DeRemer D
    Am J Health Syst Pharm; 2013 Apr; 70(7):589-97. PubMed ID: 23515511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.
    Gualberto A
    Expert Opin Investig Drugs; 2012 Feb; 21(2):205-16. PubMed ID: 22127011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study.
    Bröckelmann PJ; Zagadailov EA; Corman SL; Chirikov V; Johnson C; Macahilig C; Seal B; Dalal MR; Illidge T
    Eur J Haematol; 2017 Dec; 99(6):553-558. PubMed ID: 28949403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of brentuximab vedotin (SGN-35) in Hodgkin lymphoma patients undergoing reduced intensity allogeneic stem cell transplant following a relapse after autologous transplant.
    Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):20. PubMed ID: 25768999
    [No Abstract]   [Full Text] [Related]  

  • 25. Durable Responses with Brentuximab Vedotin in cHL.
    Cancer Discov; 2016 Sep; 6(9):OF1. PubMed ID: 27507410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brentuximab vedotin for treating Hodgkin's lymphoma: an analysis of pharmacology and clinical efficacy.
    Illés Á; Jóna Á; Miltényi Z
    Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):451-9. PubMed ID: 25642958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Where does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma?
    Goyal SD; Bartlett NL
    Curr Hematol Malig Rep; 2012 Sep; 7(3):179-85. PubMed ID: 22669711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brentuximab vedotin: a review of its use in patients with hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure.
    Garnock-Jones KP
    Drugs; 2013 Mar; 73(4):371-81. PubMed ID: 23494187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brentuximab vedotin desensitization in a patient with refractory Hodgkin's lymphoma.
    Arora A; Bhatt VR; Liewer S; Armitage JO; Bociek RG
    Eur J Haematol; 2015 Oct; 95(4):361-4. PubMed ID: 25892213
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibodies and antibody-drug conjugates in the treatment of Hodgkin lymphoma.
    Eichenauer DA; Engert A
    Eur J Haematol; 2014 Jul; 93(1):1-8. PubMed ID: 24750367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy for the treatment of Hodgkin lymphoma.
    Donato EM; Fernández-Zarzoso M; De La Rubia J
    Expert Rev Hematol; 2017 May; 10(5):417-423. PubMed ID: 28359170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.
    Martino M; Festuccia M; Fedele R; Console G; Cimminiello M; Gavarotti P; Bruno B
    Expert Opin Biol Ther; 2016; 16(3):347-64. PubMed ID: 26652934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel agents for the treatment of Hodgkin lymphoma.
    Dumaswala K; Mehta A
    Expert Rev Hematol; 2015 Oct; 8(5):659-67. PubMed ID: 26343891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells.
    Ansell SM
    Expert Opin Investig Drugs; 2011 Jan; 20(1):99-105. PubMed ID: 21121873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brentuximab vedotin in combination with extended field radiotherapy as salvage treatment for primary refractory Hodgkin lymphoma.
    Dozzo M; Zaja F; Volpetti S; Sperotto A; Magli A; Fanin R
    Am J Hematol; 2015 Apr; 90(4):E73. PubMed ID: 25546725
    [No Abstract]   [Full Text] [Related]  

  • 36. Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin.
    Mei M; Thomas S; Chen R
    BioDrugs; 2014 Jun; 28(3):245-51. PubMed ID: 24258497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of antibody-drug conjugate brentuximab vedotin in treating Hodgkin's lymphoma.
    Viviani S; Guidetti A
    Expert Opin Biol Ther; 2018 Aug; 18(8):841-849. PubMed ID: 29999431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brentuximab vedotin in systemic T-cell lymphoma.
    Oki Y; Younes A
    Expert Opin Biol Ther; 2012 May; 12(5):623-32. PubMed ID: 22428917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data.
    Bonthapally V; Wu E; Macalalad A; Yang H; Shonukan O; Liu Y; Chi A; Huebner D
    Curr Med Res Opin; 2015 May; 31(5):993-1001. PubMed ID: 25772232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
    Illidge T; Bouabdallah R; Chen R; Gopal AK; Moskowitz CH; Ramchandren R; Shustov AR; Tilly H; Trippett TM; Gibb A; Grove LE; Advani R
    Leuk Lymphoma; 2015 Mar; 56(3):703-10. PubMed ID: 24913507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.